TL;DR: Patient Stratification in Clinical Trials
- Predictive biomarkers require trial designs that validate treatment benefit in biomarker-defined subgroups (Mandrekar & Sargent, 2009)
- Enrichment strategies must match biomarker credentials; not every marker justifies a selected population (Freidlin & Korn, 2014)
- Prognostic and predictive biomarkers answer different questions; mixing them breaks enrichment logic (Buyse et al., 2011)
- Master protocols can test multiple therapies under shared stratification rules (Woodcock & LaVange, 2017)
- Motif surfaces literature evidence with PMIDs; enrollment and clinical decisions remain yours
From the Motif team: We extract predictive and prognostic biomarker evidence from published literature: population modifiers, interaction p-values, and conflicting results across cohorts, each tied to a PMID. Motif does not enroll patients, run clinical decision support, or replace biostatistical planning for your trial.
Clinical trials fail for many reasons, but heterogeneous populations dilute treatment effects when only a subgroup benefits. Before writing enrichment criteria, teams need published evidence on which biomarkers predict response or prognosis in their indication, not a generic list of marker names.
Why Heterogeneity Dilutes Treatment Effects
Simon (2005) outlined how genomic classifiers for treatment selection require rigorous development and validation pathways before they influence care.1 When trials enroll broad populations, true treatment effects in biomarker-positive patients can be statistically invisible among non-responders.
Mandrekar and Sargent (2009) review clinical trial designs for predictive biomarker validation, including enrichment, stratified, and hybrid strategies.2 The design must match the biomarker claim you intend to make at the end of the study.
Predictive vs. Prognostic: Do Not Mix Them Up
Buyse et al. (2011) explain why biomarker validation is statistically hard: prognostic markers describe outcome regardless of treatment, while predictive markers modify treatment benefit.3 Enrichment for a predictive claim requires evidence that the biomarker interacts with treatment, not merely that it correlates with prognosis.
Freidlin and Korn (2014) argue that enrichment strategies must align with how strong the biomarker evidence is at the start of the program.4 Weak discovery evidence should not automatically become a hard inclusion criterion without a validation plan.
Design Options Once Evidence Exists
Enrichment and Stratified Designs
Enrichment trials restrict enrollment to biomarker-positive patients when prior evidence supports larger treatment effects in that subgroup. Stratified designs randomize within biomarker-defined strata. Mandrekar and Sargent (2009) compare when each approach is appropriate.2
Adaptive and Platform Trials
Berry (2012) reviewed adaptive clinical trial methods that allow pre-specified design changes based on accumulating data.5 Woodcock and LaVange (2017) describe master protocols that study multiple therapies or diseases under shared infrastructure.6 Lung-MAP is a published example of a biomarker-driven platform in thoracic oncology (Liu et al., 2021).7
Literature Evidence Before the Protocol Locks
Motif is built for the evidence-scoping step, not patient enrollment:
- Ask a stratification question in plain language (e.g., predictive biomarkers for checkpoint inhibitors in a tumor type)
- Search PubMed, PMC, and Europe PMC; audit title-and-abstract screening in search provenance
- Extract predictive and prognostic associations with effect sizes, comparators, and interaction p-values
- Inspect modifiers (stage, line of therapy, molecular subtype, cohort identifier)
- Detect flips when the same biomarker shows opposing effects in different strata
- Export cited associations for protocol background or statistical analysis plan sections
Failure modes we see in stratification workflows:
- Using a prognostic literature base to justify a predictive enrichment criterion
- Ignoring papers that report null interaction tests
- Pooling studies that used incompatible assay cutoffs for PD-L1 or TMB
- Assuming Motif output replaces sample-size calculation with your biostatistician
Regulatory and Diagnostic Coordination
Companion diagnostics and biomarker qualification programs require analytical and clinical validity evidence beyond literature review. FDA-NIH BEST definitions separate analytical validity, clinical validity, and clinical utility (FDA-NIH, 2016).8 Literature mining helps you map what is already published; it does not replace assay validation or IDE/IVD strategy.
Before designing enrichment criteria, teams need published evidence on predictive and prognostic biomarkers, including subgroup modifiers and conflicting findings across cohorts. Motif surfaces stratification evidence from literature with PMIDs; it does not enroll patients or run clinical decision support. For the broader precision-medicine context, read our blog on personalized medicine biomarker analysis to learn more. For immunotherapy-specific predictors, read our blog on immunotherapy biomarkers to learn more.
References
- Simon, R. (2005). Roadmap for developing and validating therapeutically relevant genomic classifiers. Journal of Clinical Oncology, 23(29), 7332-7341. PMID: 16145063
- Mandrekar, S.J., & Sargent, D.J. (2009). Clinical trial designs for predictive biomarker validation. Journal of Clinical Oncology, 27(24), 4027-4034. PMID: 19597023
- Buyse, M., et al. (2011). Biomarkers and surrogate end points: the challenge of statistical validation. Nature Reviews Clinical Oncology, 7(6), 309-317. PMID: 20368571
- Freidlin, B., & Korn, E.L. (2014). Biomarker enrichment strategies: matching trial design to biomarker credentials. Nature Reviews Clinical Oncology, 11(2), 81-90. PMID: 24281059
- Berry, D.A. (2012). Adaptive clinical trials in oncology. Nature Reviews Clinical Oncology, 9(4), 199-207. PMID: 22064461
- Woodcock, J., & LaVange, L.M. (2017). Master protocols to study multiple therapies, multiple diseases, or both. New England Journal of Medicine, 377(1), 62-70. PMID: 28679092
- Liu, S.V., et al. (2021). The National Cancer Institute thoracic malignancies steering committee lung master protocol (Lung-MAP study). Clinical Cancer Research, 27(1), 4-11. PMID: 33037066
- FDA-NIH Biomarker Working Group. (2016). BEST (Biomarkers, EndpointS, and other Tools) Resource. PMID: 27010052
